Roche Holding AG
SIX:ROG
Roche Holding AG
Total Equity
Roche Holding AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Roche Holding AG
SIX:ROG
|
Total Equity
CHf33.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Novartis AG
SIX:NOVN
|
Total Equity
$46.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Total Equity
$1.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Total Equity
CHf196.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Total Equity
$9.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
What is Roche Holding AG's Total Equity?
Total Equity
33.8B
CHF
Based on the financial report for Dec 31, 2025, Roche Holding AG's Total Equity amounts to 33.8B CHF.
What is Roche Holding AG's Total Equity growth rate?
Total Equity CAGR 10Y
5%
Over the last year, the Total Equity growth was 6%. The average annual Total Equity growth rates for Roche Holding AG have been 6% over the past three years , -1% over the past five years , and 5% over the past ten years .
